Format

Send to

Choose Destination
Rev Med Inst Mex Seguro Soc. 2015;53 Suppl 2:S212-7.

[Epigenetic alterations in cervical cancer progression].

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

1
Unidad de Investigación Médica en Enfermedades Oncológicas, Laboratorio de Oncología Molecular, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Distrito Federal, México. 1307patricia@gmail.com.

Abstract

in English, Spanish

Despite the use of the screening test, such as Papanicolaou, and the detection of human papillomavirus (HPV), cervical cancer remains as a public health problem in México and it is the second leading cause of death for malignant neoplasias among women. High-risk HPV infection is the main risk factor for the development of premalignant lesions and cervical cancer; however, HPV infection is not the only factor; there are various genetic and epigenetic alterations required for the development of neoplasias; some of them have been described and even in some cases they have been suggested as biomarkers for prognosis. However, in contrast with other cancer types, such as breast cancer, in cervical cancer the use of biomarkers has not been established for clinical applications. Unlike genetic alterations, epigenetic alterations are potentially reversible; in this sense, their characterization is important, since they have not only a potential use as biomarkers, but they also could represent new therapeutic targets for treatment of cervical cancer. This review describes some of the more common epigenetic alterations in cervical cancer and its potential use in routine clinical practice.

KEYWORDS:

Biomarkers; Cervical cancer; Epigenetics

PMID:
26462519
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center